Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11741377 | 0.79 | MAPT (0.58) | CA12CA9MAPTCA1CA2 | |
| SCHEMBL1120433 | 0.78 | PYCR1 (0.39) | CA12CA9MAPTCA1CA2 | |
| SCHEMBL28186756 | 0.77 | PYCR1 (0.53) | CA12CA9MAPTCA1CA2 | |
| SCHEMBL11078522 | 0.77 | MAPT (0.53) | CA12CA9MAPTCA1CA2 | |
| SCHEMBL31592520 | 0.77 | CA12 (0.53) | CA12CA9MAPTCA1CA2 | |
| SCHEMBL566097 | 0.77 | MAPT (0.53) | CA12CA9MAPTCA1CA2 | |
| SCHEMBL17076659 | 0.77 | CA12 (0.58) | CA12CA9MAPTCA1CA2 | |
| SCHEMBL5697708 | 0.77 | CA2 (0.46) | CA9MAPTCA2CYP1A2CYP2C9 | |
| SCHEMBL7439011 | 0.77 | MEN1 (0.43) | MAPTCA1CA2CYP1A2CYP2C9 | |
| SCHEMBL7648250 | 0.77 | MAPT (0.45) | CA12CA9MAPTCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055091-A1 | NAPHTHOQUINONE DERIVATIVE AND MEDICAL USE THEREOF | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2026-02-26 | — | — | US | disclosed |
| CN-119161324-A | Methods and compounds for restoring mutant p53 function | 皮姆维制药公司 | 2024-12-20 | — | — | CN | disclosed |
| CN-117510507-A | Palladium-catalyzed indoline quinoline derivative synthesized by intramolecular dearomatization of indole and preparation method thereof | 河北工业大学 | 2024-02-06 | — | — | CN | disclosed |
| US-20220213062-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2022-07-07 | — | — | US | disclosed |
| US-11339141-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| CN-109336829-B | Aryl formamide compound containing 1,2, 3-triazole structure and application thereof | 沈阳药科大学 | 2022-03-01 | — | — | CN | disclosed |
| US-10889546-B2 | Alkynyl pyridine prolyl hydroxylase inhibitor, and preparation method and medical use thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2021-01-12 | — | — | US | disclosed |
| US-20210002252-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2021-01-07 | — | — | US | disclosed |
| US-20200407319-A1 | ALKYNYL PYRIDINE PROLYL HYDROXYLASE INHIBITOR, AND PREPARATION METHOD AND MEDICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. | 2020-12-31 | — | — | US | disclosed |
| CN-107848976-B | Alkynyl pyridine prolyl hydroxylase inhibitor, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2020-11-17 | — | — | CN | disclosed |
| US-20190119249-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2019-04-25 | — | — | US | disclosed |
| EP-3416638-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV Pharmaceuticals, Inc. (US) | 2018-12-26 | — | — | EP | disclosed |
| US-10138219-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS (US) | 2018-11-27 | — | — | US | disclosed |
| US-20180305317-A1 | ALKYNYL PYRIDINE PROLYL HYDROXYLASE INHIBITOR, AND PREPARATION METHOD AND MEDICAL USE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2018-10-25 | — | — | US | disclosed |
| US-20170240525-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2017-08-24 | — | — | US | disclosed |
| WO-2017143291-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2017-08-24 | — | — | WO | disclosed |
| EP-2245020-B1 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2014-01-15 | — | — | EP | disclosed |
| US-8383657-B2 | Thiazolylidine urea and amide derivatives and methods of use thereof | ABBOTT LABORATORIES (US) | 2013-02-26 | — | — | US | disclosed |
| US-20090163470-A1 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-06-25 | — | — | US | disclosed |
| EP-0365763-A1 | Antiproliferative cyclic compounds | AGOURON PHARMACEUTICALS, INC. (US) | 1990-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180305317-A1 | ALKYNYL PYRIDINE PROLYL HYDROXYLASE INHIBITOR, AND PREPARATION METHOD AND MEDICAL USE THEREOF | EGLN3, EGLN2, EPOR | CA12 4360/4885CA9 2073/4885MAPT 3982/4885 |
| US-20170240525-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, KRAS | CA12 3754/4885CA9 3772/4885MAPT 4269/4885 |
| US-20090163470-A1 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | NMUR1, NMUR2, PAM | CA12 2742/4885CA9 1201/4885MAPT 465/4885 |
| US-11339141-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, KRAS | CA12 3754/4885CA9 3772/4885MAPT 4269/4885 |
| US-20220213062-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, KRAS | CA12 3754/4885CA9 3772/4885MAPT 4269/4885 |
| US-20190119249-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, KRAS | CA12 3754/4885CA9 3772/4885MAPT 4269/4885 |
| US-20260055091-A1 | NAPHTHOQUINONE DERIVATIVE AND MEDICAL USE THEREOF | NFATC1, IL17A, AHR | CA12 4181/4885CA9 1360/4885MAPT 3447/4885 |
| US-10889546-B2 | Alkynyl pyridine prolyl hydroxylase inhibitor, and preparation method and medical use thereof | EGLN3, EGLN2, EPOR | CA12 4360/4885CA9 2073/4885MAPT 3982/4885 |
| US-20210002252-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, KRAS | CA12 3754/4885CA9 3772/4885MAPT 4269/4885 |
| US-20200407319-A1 | ALKYNYL PYRIDINE PROLYL HYDROXYLASE INHIBITOR, AND PREPARATION METHOD AND MEDICAL USE THEREOF | EGLN3, EGLN2, EPOR | CA12 4360/4885CA9 2073/4885MAPT 3982/4885 |
| US-10138219-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, KRAS | CA12 3754/4885CA9 3772/4885MAPT 4269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.